Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 8/20 | 0.43 |
| ▸ | HTR2C | P28335 | 3/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | MC4R | P32245 | 4/20 | 0.42 |
| ▸ | FPR1 | P21462 | 3/20 | 0.41 |
| ▸ | FPR2 | P25090 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12104061 | 1.00 | PRCP (0.43) | PRCPHTR2CHTR2AHTR2BMC4R | |
| SCHEMBL684171 | 0.85 | PRCP (0.45) | PRCPHTR2CHTR2AHTR2BMC4R | |
| SCHEMBL8223289 | 0.85 | PRCP (0.45) | PRCPHTR2CHTR2AHTR2BMC4R | |
| SCHEMBL29904547 | 0.84 | PRCP (0.46) | PRCPHTR2CHTR2AHTR2BMC4R | |
| SCHEMBL14310837 | 0.83 | HTR2C (0.46) | PRCPHTR2CHTR2AHTR2BMC4R | |
| Hydrochloric Acid SCHEMBL28643755 | 0.83 | HTR2C (0.46) | PRCPHTR2CHTR2AHTR2BMC4R | |
| SCHEMBL13012434 | 0.83 | HTR2C (0.43) | PRCPHTR2CHTR2AHTR2BMC4R | |
| SCHEMBL21036774 | 0.82 | FPR1 (0.44) | PRCPHTR2CHTR2AHTR2BMC4R | |
| SCHEMBL21036775 | 0.82 | FPR1 (0.44) | PRCPHTR2CHTR2AHTR2BMC4R | |
| SCHEMBL679794 | 0.82 | PRCP (0.43) | PRCPHTR2CHTR2AHTR2BMC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2966065-A2 | HYDROXYLATED AND METHOXYLATED CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2016-01-13 | — | — | EP | disclosed |
| US-8063050-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051399-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | PRCP 2180/4885HTR2C 1003/4885HTR2A 1733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.